Hyderabad: The New Emerging Edition of the Concern B.1.1.529 (omicron) may not respond to monoclonal antibody therapy or cocktail treatment, experts fear.
Based on a preliminary analysis of Omicron infections in South Africa and elsewhere, experts suggest its spreading potential (R value) is six times higher than delta The variant that triggered the second wave in India. It can also evade the immune system. this can also be the reason Vaccination successful transition.
The delta variant, which causes heavy infection and mortality, responds to monoclonal antibody therapy. However, its descendant, the Delta Plus, did not respond to this therapy, which is considered a miracle cure for COVID-19 in the early stages of infection. After Delta Plus, Omicron is the second type of concern that may not respond to monoclonal antibody treatment.
According to IGIB research scholar Mercy Rofina, the new lineage has a total of 53 variants, including 32 spike protein variants. “Most of the observed forms have resistance against immunity and other functional effects. Six variants with spike receptor binding domains at G339D, S373P, G496S, Q498R and Y505H are found to be resistant to monoclonal antibodies (mAbs), including etesevimab, bamlanivimab , casirivimab, imdevimab and their cocktails,” Rofina tweeted.
In a series of tweets on the new variant, Scaria, an expert in genome science, said that at least one case of B.1.1.529 in Israel has received a Covid-19 vaccine booster, suggesting that the variant is a vaccine success. may cause infection. ,
“The severity of the disease is yet to be ascertained, which is the most important point to consider. While vaccine success infection per se is not the major concern (delta also causes vaccine breakthrough infection), transmissibility and clinical outcome (severity and mortality) are key points,” he said.
Rofina, who is from Scaria’s lab, compiled the structural reference to the immune escape mutation in Omicron.
Scaria said the three mutations in the S1/S2 furin cleavage site probably suggest better cell entry (and there may be transmissibility). However, he noted that the properties of a single mutation do not always add up when they occur in combination. Nevertheless, they provide possible directions to explore.
“Despite the potential for bias in sequencing, version B.1.1.1.529 is becoming effective (around 0 to 75% in 2 weeks) in South Africa. Further sequences and data are awaited in the coming days. B. The .1.1.529 variant was spreading rapidly in South Africa, faster than other variants of concern we have seen in the past,” Scaria said in her tweet.
Based on a preliminary analysis of Omicron infections in South Africa and elsewhere, experts suggest its spreading potential (R value) is six times higher than delta The variant that triggered the second wave in India. It can also evade the immune system. this can also be the reason Vaccination successful transition.
The delta variant, which causes heavy infection and mortality, responds to monoclonal antibody therapy. However, its descendant, the Delta Plus, did not respond to this therapy, which is considered a miracle cure for COVID-19 in the early stages of infection. After Delta Plus, Omicron is the second type of concern that may not respond to monoclonal antibody treatment.
According to IGIB research scholar Mercy Rofina, the new lineage has a total of 53 variants, including 32 spike protein variants. “Most of the observed forms have resistance against immunity and other functional effects. Six variants with spike receptor binding domains at G339D, S373P, G496S, Q498R and Y505H are found to be resistant to monoclonal antibodies (mAbs), including etesevimab, bamlanivimab , casirivimab, imdevimab and their cocktails,” Rofina tweeted.
In a series of tweets on the new variant, Scaria, an expert in genome science, said that at least one case of B.1.1.529 in Israel has received a Covid-19 vaccine booster, suggesting that the variant is a vaccine success. may cause infection. ,
“The severity of the disease is yet to be ascertained, which is the most important point to consider. While vaccine success infection per se is not the major concern (delta also causes vaccine breakthrough infection), transmissibility and clinical outcome (severity and mortality) are key points,” he said.
Rofina, who is from Scaria’s lab, compiled the structural reference to the immune escape mutation in Omicron.
Scaria said the three mutations in the S1/S2 furin cleavage site probably suggest better cell entry (and there may be transmissibility). However, he noted that the properties of a single mutation do not always add up when they occur in combination. Nevertheless, they provide possible directions to explore.
“Despite the potential for bias in sequencing, version B.1.1.1.529 is becoming effective (around 0 to 75% in 2 weeks) in South Africa. Further sequences and data are awaited in the coming days. B. The .1.1.529 variant was spreading rapidly in South Africa, faster than other variants of concern we have seen in the past,” Scaria said in her tweet.
,